PSYCHPSYCHPSYCH
  • REPORT
  • THE PSYCH SUMMIT
  • NEWS AND INSIGHTS
  • NEWSLETTER
  • REPORT
  • THE PSYCH SUMMIT
  • NEWS AND INSIGHTS
  • NEWSLETTER
  • UNLOCKING THE COMMERCIAL POTENTIAL OF PSYCHEDELICS
    DOWNLOAD THE REPORT
    SUBSCRIBE TO NEWSLETTER

OUR MISSION

The global psychedelics industry is expected to be worth over US$100 billion with the potential to save $1 trillion on lost productivity, disrupting the way we approach healthcare. As attitudes towards psychedelics shift dramatically, we are witnessing an international rise in clinical trials, academic research and commercial investment. The use of psychedelics as medicine is set to open up a new industry at pace. We help investors, operators and regulators navigate the many opportunities through data, intelligence and networking.

OFFERING

We demystify the legislative and regulatory environment surrounding a variety of psychedelics, helping our clients to navigate the changing landscape of each region.

We provide market forecasts and estimates for potential savings to society/economy which are likely to result from psychedelic therapies over the next decade.

We identify and analyse emerging trends for individual psychedelic therapies and monitor innovation and developments in this exciting, burgeoning industry.

THE PSYCHEDELICS AS MEDICINE REPORT: SECOND EDITION

DISRUPTING MODERN HEALTHCARE

Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation. The Psychedelics as Medicine Report: Second Edition provides unparalleled consumer insights and market intelligence from experts and industry leaders, helping to guide investors, operators and regulators through this transient phase. Download your free copy now.


The Psychedelics as Medicine Report: Second Edition examines:

  • Proprietary consumer insights on attitudes, uses and behaviours
  • Deep dives into the most transformative compounds and companies
  • Key regulations, transformative trends and commercial opportunities

HIGHLIGHTS

PSYCH: What are the next steps
for investors?

PSYCH: What Lies Ahead?
The Future of Therapy

PSYCH: Psychedelics for
Substance Use

PSYCH: Lessons Learned from 50 Years of Psychedelic Activism

NEWS AND INSIGHTS

Results of Major Study on Impact of Microdosing Published

Researchers from Imperial College London have carried out the largest placebo-controlled trial into psychedelics to date and found that small doses of LSD boost the psychology of users in a manner of ways. However, when the researchers examined what trial volunteers took, they found placebos worked equally as well as the drug. In short, theContinue reading

Read more

An Analysis of Microdosing Psychedelics

During The PSYCH Symposium in November 2020, a panel of leading scientists discussed their work in the field of psychedelic medicines as well as the research they had conducted on microdosing and the impact it has on the human body. Does it increase creativity? Improve focus or nothing more than a silicon valley fad? FindContinue reading

Read more

When Mother Nature Becomes Big Business

During The PSYCH Symposium in November 2020, a panel of leading experts operating in psychedelics sector, discussed the cultural challenge of commercialising the likes of psilocybin, DMT and LSD. This discussion, featuring a number of leading voices from across the psychedelics spectrum, focused on the problems which may arise as a result of removing theContinue reading

Read more

THE PSYCHEDELICS NEWSLETTER

Expert analysis and intelligence, straight to your inbox. Join industry insiders and subscribe for exclusive news, data and insights from across the psychedelics industry.

ISSUES

Issue 17

The results of a study on the use of MDMA to treat alcohol addiction have been published this week, whilst reforms on the use of psychedelics continue to take shape across the US.

Enjoy Issue 17 of The Psychedelics Newsletter, here.

 

Issue 18

Researchers have published the results on the most comprehensive study on microdosing while European psychedelic companies have been given an edge in the international market.

Enjoy Issue 18 of The Psychedelics Newsletter, here.

 

FOLLOW US ON TWITTER

MAPS @MAPS

Legal #Psychedelic Therapies Will Offer #Healthcare Cost Savings of Billions of Dollars
http://maps.org/20210305b via Psych of Prohibition Partners (@Psych_PP)

MAPS Study: #MDMA-Assisted #Therapy Will Be Cost-Effective in the Treatment of #PTSD
http://maps.org/20210305c

Twitter 1367993328525062152
PSYCH @psych_pp

"Given the escalating magnitude of the mental health crisis, the need to address this epidemic has never been as accentuated. We strongly believe that the growth potential within this industry is of staggering proportions."

Sa'ad Shah, @NoeticFund

https://www.accesswire.com/viewarticle.aspx?id=633339

Twitter 1367585165141106695
PSYCH @psych_pp

The German startup @ATAI_life, which is exploring the use of psychedelic substances to treat mental health disorders, has been valued at about US$2 billion in a funding round ahead of its potential listing.
https://www.bloomberg.com/news/articles/2021-03-03/thiel-backed-magic-mushroom-firm-atai-hits-2-billion-valuation

Twitter 1367480664564633603
PSYCH @psych_pp

The PSYCH Virtual Investor Summit: Europe & Asia, will connect a qualified investor community in Europe and Asia with the leaders from the most innovative and exciting businesses operating in the global psychedelic industry.

Secure your place, here:
https://form.typeform.com/to/N9UNFeaZ

Twitter 1367472617654022145
Awakn™ Life Sciences @awakn_ls

Awakn announces intent to pursue qualifying transaction in preparation for listing on the NEO Exchange in Canada.

Here's the press release:
https://finance.yahoo.com/news/1169082-b-c-ltd-announces-120000570.html

Twitter 1367468245297553418
PSYCH @psych_pp

🔬Results of major microdosing trial published
💊Phase III Ketamine trial launched by @awakn_ls
🇪🇺 Europe to play leading role in psychedelics sector

All this and more in Issue 18 of The Psychedelics Newsletter:
https://psych.prohibitionpartners.com/psych_weekly/issue-18/

Twitter 1367190643378966539
Load More...
+44 (0) 203 928 2814
20-22 Wenlock Road, London, N1 7GU, United Kingdom

 

©2021 PP Intelligence LTD. (t/a PSYCH)

Privacy Policy